The Torrence E. Hemby Jr., Pediatric Hematology and Oncology Center offers more than 60 clinical trials through the Children's Oncology group, which is an international pediatric oncology consortium. The Center's pediatric patients also have access to a broad range of clinical research studies, including National Cancer Institute protocols for therapies under development.
We are proudly affiliated with Blumenthal Cancer Center on the campus of Carolinas Medical Center, which allows our center to conduct cutting-edge clinical trials.
More recently, the Center has joined two widely recognized consortia dedicated to fighting childhood cancer. These include Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), and the Neuroblastoma and Medulloblastoma Translational Research Consortium. Affiliation with these organizations will give children in the Carolinas access to novel drugs which were previously not available in the Carolinas.
Phase I and Phase II clinical trials planned by the Center will focus on leukemia, lymphoma, neuroblastoma, brain tumors, kidney cancer, and other bone and soft tissue tumors.
"Clinical research is an essential element of our mission at Levine Children's Hospital," said Dr. Leonard Feld, Sara H. Bissell & Howard C. Bissell Endowed Chair in Pediatrics and Chief Medical Officer of Levine Children's Hospital. "The expansion of Phase I and Phase II studies will lead to increasing our overall knowledge and enhancing the capability of our physicians and staff to provide new treatment options for our region's children with cancer."
The Developmental Therapeutics program's mission is to bring Phase I & II clinical trials to the Charlotte area so no child ever has to leave the area for their care.
Phase I & II clinical trials bring new and exciting therapies for children that are currently not offered in the Carolinas.
The program continues to reach out to the community for ongoing donations to expand the number of clinical trials it can offer.
It has already become members of 2 national consortiums that treat patients with recurrence of leukemia, neuroblastoma, and medulloblastoma
National Consortium Participation
Neuroblastoma and Medulloblastoma Translational Research Consortium
Levine Children's Hospital is one of eight members of NMTRC (www.nmtrc.org), a group of universities and children's hospitals that came together to offer a national network of clinical trials. These trials are based on the research derived from a group of closely collaborating investigators who are linked with laboratory programs developing new therapies for high-risk neuroblastoma and medulloblastoma.
Levine Children's Hospital is currently participating in the current study: Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
To learn more about the NMTRC you may visit their website.
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
Levine Children's Hospital is one of 33 members of TACL.TACL was established to provide a means for carrying out early studies of new drugs in children with recurrent leukemia or lymphoma. TACL is supported by, and the Operations Office is housed within, the USC-CHLA Institute for Pediatric Clinical Research.
To learn more about TACL you may visit their website.
Meet the DVL Team : DVL Information for Families : Clinical Trials :
For Health Professionals : DVL Home